Amneal Pharmaceuticals (NASDAQ:AMRX) Issues FY 2025 Earnings Guidance

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share guidance of 0.650-0.70 for the period, compared to the consensus earnings per share estimate of 0.680. The company issued revenue guidance of $3.0 billion-$3.1 billion, compared to the consensus revenue estimate of $3.0 billion.

Amneal Pharmaceuticals Stock Up 3.0 %

AMRX traded up $0.23 during trading on Friday, reaching $7.97. 4,829,305 shares of the company were exchanged, compared to its average volume of 1,414,630. Amneal Pharmaceuticals has a 12-month low of $6.29 and a 12-month high of $9.48. The company's 50-day moving average is $8.02 and its two-hundred day moving average is $8.16. The company has a market cap of $2.47 billion, a price-to-earnings ratio of -11.72 and a beta of 1.17.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its quarterly earnings data on Friday, May 2nd. The company reported $0.19 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.05. The company had revenue of $695.42 million during the quarter, compared to analyst estimates of $714.78 million. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. Equities analysts forecast that Amneal Pharmaceuticals will post 0.53 earnings per share for the current year.

Analyst Ratings Changes

AMRX has been the subject of a number of research reports. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their price target for the stock from $9.00 to $12.00 in a research note on Monday, February 24th. Barclays increased their target price on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an "overweight" rating in a research note on Monday, March 3rd. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $10.80.

Insider Activity at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the sale, the insider now directly owns 48,578,209 shares of the company's stock, valued at approximately $405,628,045.15. The trade was a 9.33 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Gautam Patel sold 80,000 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $8.14, for a total value of $651,200.00. Following the completion of the transaction, the director now directly owns 1,888,886 shares of the company's stock, valued at $15,375,532.04. This represents a 4.06 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,160,000 shares of company stock worth $43,113,200 over the last quarter. 26.56% of the stock is owned by corporate insiders.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.